HQY
Strong BuyPremium GrowerAI pickHealthEquity, Inc. · Healthcare · United States · $8.6B cap · $86.8M/day traded
$101.36 +0.0% · close 29 Oct · scored 30 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
As of 30 Oct 2026, MoatMap's StockRank for HealthEquity, Inc. (HQY) is 83/100, ranked against 24,000+ stocks in 35 markets (Quality 71, Value 37, Momentum 71, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
HealthEquity is the largest US custodian of health savings accounts, with a record $37.9 billion of HSA assets. Employers and members rarely switch providers, so revenue is sticky, and a large part of profit comes from the interest earned on custodial cash, which benefits directly if US rates stay higher for longer. The company just reported record revenue with margin expansion and raised its fiscal 2027 guidance, yet the share price fell about 10% on the day, and it has been repurchasing shares (about 1.46% of the stock in the past 90 days). Recent US legislation has also widened HSA eligibility, extending the growth runway in accounts and assets.
ABOUT HEALTHEQUITY, INC.
Read
HealthEquity, Inc. is a leading independent administrator of health savings accounts (HSAs) and other consumer-directed benefits (CDBs), providing a technology-driven platform for managing healthcare finances. The company's competitive moat is built on its extensive network of employer and health plan partners, high customer retention due to sticky accounts, and a comprehensive platform that simplifies healthcare saving and spending. As a market leader, HealthEquity benefits from the increasing adoption of HSAs and the complexity of healthcare finance.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 756.6M | 861.7M | 999.6M | 1.2B | 1.3B | 14.8% | 1.4B | 1.4B | 1.5B | 7.8% |
| EPS | -0.53 | -0.31 | 0.65 | 1.11 | 2.50 | 96.1% | 2.77 | 2.95 | 3.44 | 17.3% |
| Shares | 83.8M | 84.8M | 86.1M | 86.5M | 85.0M | +1.5% | 82.7M | — | — | — |
| Debt | 1.0B | 994.5M | 933.1M | 1.1B | 1.0B | -0.2% | 971.0M | — | — | — |
| Equity | 1.9B | 1.9B | 2.0B | 2.1B | 2.1B | 3.3% | — | — | — | — |
| Op CF | 141.0M | 150.7M | 242.8M | 339.9M | 457.1M | 34.2% | 490.2M | — | — | — |
| Inv CF | -639.2M | -119.1M | -46.1M | -505.5M | -47.1M | — | — | — | — | — |
| Fin CF | 394.9M | -2.7M | -47.0M | 57.6M | -387.0M | — | — | — | — | — |
Above its 200-day average and 6% below its 52-week high.
Calmer than 63% of stocks we rank over the past year (35% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HQY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HQY | HealthEquity, Inc.(you) | $8.6B | 83 | Strong Buy |
| HNGE | Hinge Health, Inc. | $9.0B | 75 | Buy |
| BTSG | BrightSpring Health Services, Inc. | $11.9B | 80 | Strong Buy |
| DOCS | Doximity, Inc. | $6.0B | 76 | Buy |
| WAY | Waystar Holding Corp. | $5.5B | 75 | Buy |
| VEEV | Veeva Systems Inc. | $52.3B | 82 | Strong Buy |
| GDRX | GoodRx Holdings, Inc. | $1.2B | 83 | Strong Buy |
| HSTM | HealthStream, Inc. | $1.1B | 80 | Strong Buy |
| TEM | Tempus AI, Inc. | $12.3B | 41 | Hold |
| CERT | Certara, Inc. | $1.6B | 67 | Buy |
Peer medians: ROE -30.5% · P/E 27.2x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.